What the Research Shows
A neuroscientist at Radboud University's Donders Institute has published a landmark finding in Science Advances: targeted ultrasonic sound waves, directed precisely at specific brain regions, can help the brain extinguish fear responses significantly faster than it would on its own. Researcher Sjoerd Meijer demonstrated for the first time that this technique — known as transcranial focused ultrasound (tFUS) — can modulate the neural circuitry involved in fear learning and extinction without surgery or drugs.
Fear extinction is the process by which the brain learns that something previously associated with danger is now safe. It's central to nearly every evidence-based treatment for PTSD and anxiety disorders, including exposure therapy, EMDR, and increasingly, ketamine-assisted psychotherapy. When extinction works well, patients can revisit traumatic associations without triggering a full threat response. When it doesn't — when the brain remains locked in a pattern of threat reactivity — recovery stalls. This new research targets exactly that bottleneck. Read the original coverage at Medical Xpress.
Why Fear Extinction Matters So Much in Ketamine Treatment
Ketamine's therapeutic mechanism in PTSD and trauma-related depression isn't fully understood, but one of its most compelling proposed actions is its ability to open a window of neuroplasticity — a period of heightened synaptic flexibility during which old fear associations can be rewired more easily. Researchers have described this as a "critical window" that typically lasts hours to days after an infusion, during which therapeutic work, exposure exercises, or integration sessions can have outsized impact.
The Radboud finding is relevant here because it suggests another tool may be able to target that same extinction process — the brain's capacity to overwrite a fear memory with a safety signal. If tFUS can accelerate extinction independently, the logical next question is what happens when it is paired with interventions that already prime neuroplasticity. Ketamine is one of the most potent neuroplasticity-enhancing agents currently in clinical use. A combination approach — using focused ultrasound to target specific fear circuits during or after a ketamine session — is a plausible and scientifically grounded direction for future research.
This isn't speculative leaping. Combination neurostimulation strategies are already being explored in treatment-resistant depression. Transcranial magnetic stimulation (TMS) combined with ketamine infusions is an active area of clinical investigation, with several trials showing additive or synergistic benefits. Focused ultrasound offers something TMS currently cannot: spatial precision reaching deep subcortical structures, including the amygdala and hippocampus — the core nodes of fear memory — without the skull-surface limitations of magnetic stimulation.
Key Takeaway for Patients
This research is early-stage and not yet in clinical use. Focused ultrasound for fear extinction has been demonstrated in a research setting — it has not been validated as a standalone treatment for PTSD or anxiety disorders. Do not delay or substitute evidence-based care based on this finding. However, it's worth discussing with your provider if you're exploring a multimodal approach to trauma treatment, as the neurobiological rationale for combining ultrasound with ketamine therapy is genuinely compelling.
What This Means for Patients and Providers in 2026
For patients currently in or considering ketamine therapy for PTSD, treatment-resistant depression, or anxiety, this research is a useful signal about where the field is heading — not a reason to change anything you're doing today. Fear extinction is already one of the goals of well-structured ketamine-assisted psychotherapy. Skilled providers design the integration window around precisely this: helping patients process and recontextualize fear-based memories while the brain is in a state of heightened flexibility. The ultrasound research validates that framework neurobiologically while pointing toward future adjunctive tools.
For providers, particularly those working at the intersection of ketamine and trauma-focused psychotherapy, the Donders Institute findings are worth tracking. The amygdala-targeting precision of focused ultrasound addresses one of the persistent challenges in PTSD treatment: that verbal and cognitive therapies often struggle to reach the subcortical, pre-linguistic layers where fear is stored. Ketamine already works in part by disrupting those deep-brain patterns. A tool that can spatially amplify extinction in the same circuits, potentially at the same time, represents a meaningful step toward more targeted trauma treatment.
Patients researching clinic options should look for providers who take a neuroscience-informed approach to integration — not just infusion administration. The growing body of research on fear extinction, neuroplasticity, and combination neurostimulation underscores that what happens around a ketamine session matters as much as the infusion itself. Ask prospective clinics how they structure the post-infusion window and whether their protocols are informed by current research on memory reconsolidation and extinction learning.
The Radboud study is a reminder that ketamine therapy does not exist in isolation — it sits within a rapidly evolving landscape of brain-based interventions for anxiety and trauma. Staying informed about that landscape helps patients and caregivers make better decisions and ask better questions of their treatment teams.
Share